Provided by Tiger Trade Technology Pte. Ltd.

KEYMED BIO-B

81.550
+1.9502.45%
Volume:2.63M
Turnover:213.58M
Market Cap:24.38B
PE:-42.70
High:82.400
Open:79.500
Low:78.900
Close:79.600
52wk High:89.750
52wk Low:44.660
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:1.38
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.910
ROE:21.49%
ROA:-8.24%
PB:5.21
PE(LYR):-42.70
PS:25.00

Loading ...

Keymed Biosciences Says Phase II Trial of CM512 Meets Endpoints in Chronic Rhinosinusitis with Nasal Polyps

Reuters
·
Aug 10

Keymed Biosciences Sets 19 Aug 2026 Board Meeting to Approve 1H26 Interim Results and Consider Dividend

Bulletin Express
·
Aug 07

Movement Alert|KEYMED BIO-B Rises 5.46% in Regular Trading, Multiple Institutions Cross 5% Threshold Amid Pipeline Catalysts

Market Focus
·
Aug 07

Orient Securities Company Limited Boosts Stake in Keymed Biosciences Inc with HK$14.8 Million Acquisition

Stock News
·
Aug 06

KEYMED BIO-B: DFZQ Acquires Shares, Long Position Rises to 5.05%

HK Disclosure
·
Aug 06

The Bull Case For Keymed Biosciences (SEHK:2162) Could Change Following Key Phase III Oncology Success

Simply Wall St.
·
Aug 06

Asset Manager Raises Stake in KEYMED BIO-B with HK$14.8 Million Purchase

Stock News
·
Aug 04

Movement Alert|KEYMED BIO-B Falls 5.38% in Regular Trading, CMG901 Phase III Positive Data Triggers Sell-the-News Pressure

Market Focus
·
Jul 29

Hong Kong Stocks Edge Higher Ahead of Central Bank Meetings; Keymed Biosciences Falls

MT Newswires Live
·
Jul 28

Movement Alert|KEYMED BIO-B Falls 5.59% in Regular Trading, CMG901 Phase 3 Success Triggers Sell-the-News Reaction

Market Focus
·
Jul 28

Keymed Biosciences' Gastric Cancer Drug Meets Phase 3 Goal; Shares Fall 5%

MT Newswires Live
·
Jul 28

Keymed Biosciences Says CLARITY-Gastric01 Phase III Trial Achieves Positive Topline Results

Reuters
·
Jul 28

KeyMed Biosciences - Trial Meets Dual Primary Endpoints for Overall Survival in Advanced Gastric Cancer

THOMSON REUTERS
·
Jul 28

KeyMed Biosciences - Clarity-Gastric01 Phase Iii Trial Achieves Positive Topline Results

THOMSON REUTERS
·
Jul 28

Hong Kong Stocks Rise on Thursday; Tsaker New Energy Soars

MT Newswires Live
·
Jul 23

Keymed Bio-B Shares Surge Over 3% Following Inclusion of CM512 in China's Breakthrough Therapy Designation List

Stock News
·
Jul 23

KEYMED BIO-B's CM512 Designated as Breakthrough Therapy for Chronic Rhinosinusitis with Nasal Polyps

Stock News
·
Jul 23

Keymed Biosciences Advances Phase II Trials for CM512 Across Multiple Respiratory and Inflammatory Indications

Reuters
·
Jul 23

Keymed Biosciences Says China Regulator Grants Breakthrough Therapy Designation for CM512 in Crswnp

Reuters
·
Jul 23

Keymed Biosciences - Cm512 Included in Breakthrough Therapy Designation List for Chronic Rhinosinusitis with Nasal Polyps

THOMSON REUTERS
·
Jul 23